Novo Nordisk A/S shares rose after the Danish drugmaker withdrew from a $10 billion takeover battle for obesity drug developer Metsera Inc., clearing the way for Pfizer Inc.
Novo Nordisk Rises After Bowing Out of Metsera Takeover Battle
Related Posts
Weakest Consumers Face More Pain, Bond Data Shows: Credit Weekly
The weakest consumers are increasingly struggling, and debt investors are starting to take notice.
Inflation Stalls as Fed’s Dual Mandate in Conflict | Real Yield 8/29/2025
«Bloomberg Real Yield» highlights the market-moving news you need to know. Today’s guests: JPMorgan Asset Management Core Plus Bond ETF…
Stocks Advance as AI Strains Ease, Dollar Slips: Markets Wrap
A rally in technology shares that lifted Wall Street benchmarks extended into Asia, as concern over the disruptive effects of…